Journal Mobile Options
Table of Contents
Vol. 37, No. 3-4, 2011
Issue release date: December 2011

Pain Perception, Pain Drug Therapy and Health Status in Patients with Parkinson’s Disease

Müller T. · Muhlack S. · Woitalla D.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: Parkinson’s disease (PD) is traditionally characterized as a movement disorder; however, sensory perception problems including pain syndromes are also frequent. We performed a survey to analyze the relations between health status, pain perception and gender in 4,086 PD patients. Moreover, the participants should tick whether they took pain medications or not. Subjects and Methods: The questionnaire included the EQ-5D and visual analogue scales (VAS) on pain, which asked for mean (VAS A), most (VAS B), and minimal (VAS C) intensity of pain during an interval of 4 weeks prior to the completion of the survey. Results: PD patients were divided into three groups according to their EQ-5D total score (I: <8; II: 8–9; III: 10–15). An impairment of health status occurred in relation to the increase in pain syndromes in PD patients. There was a significant increase in VAS scores in relation to the EQ-5D group membership. Female patients reported more on pain and more frequently received a pain drug treatment than male patients. Significant associations were found between the VAS and the EQ-5D scores, and the correlation coefficients were higher in men than in women. Conclusions: Pain is associated with the health status of PD patients and worsens it. More female than male PD patients have to deal with handling of pain and pain drug treatment.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Wood PB: Role of central dopamine in pain and analgesia. Expert Rev Neurother 2008;8:781–797.
  2. Brefel-Courbon C, Grolleau S, Thalamas C, Bourrel R, Allaria-Lapierre V, Loi R, Micallef-Roll J, Lapeyre-Mestre M: Comparison of chronic analgesic drugs prevalence in Parkinson’s disease, other chronic diseases and the general population. Pain 2009;141:14–18.
  3. Negre-Pages L, Regragui W, Bouhassira D, Grandjean H, Rascol O: Chronic pain in Parkinson’s disease: the cross-sectional French DoPaMiP survey. Mov Disord 2008;23:1361–1369.
  4. Beiske AG, Loge JH, Ronningen A, Svensson E: Pain in Parkinson’s disease: prevalence and characteristics. Pain 2009;141:173–177.
  5. Tinazzi M, Del VC, Fincati E, Ottaviani S, Smania N, Moretto G, Fiaschi A, Martino D, Defazio G: Pain and motor complications in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2006;77:822–825.
  6. Gerdelat-Mas A, Simonetta-Moreau M, Thalamas C, Ory-Magne F, Slaoui T, Rascol O, Brefel-Courbon C: Levodopa raises objective pain threshold in Parkinson’s disease: a RIII reflex study. J Neurol Neurosurg Psychiatry 2007;78:1140–1142.
  7. Müller T, Woitalla D: Quality of life, caregiver burden and insurance in patients with Parkinson’s disease in Germany. Eur J Neurol 2010;17:1365–1369.
  8. Schrag A, Selai C, Jahanshahi M, Quinn NP: The EQ-5D – a generic quality of life measure – is a useful instrument to measure quality of life in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 2000;69:67–73.
  9. Siderowf AD, Werner RM: The EQ-5D – a generic quality of life measure – is a useful instrument to measure quality of life in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 2001;70:817.
  10. Rodriguez-Blazquez C, Forjaz MJ, Frades-Payo B, de Pedro-Cuesta J, Martinez-Martin P: Independent validation of the scales for outcomes in Parkinson’s disease-autonomic (SCOPA-AUT). Eur J Neurol 2010;17:194–201.
  11. Defrin R, Shramm L, Eli I: Gender role expectations of pain is associated with pain tolerance limit but not with pain threshold. Pain 2009;145:230–236.
  12. Keogh E, Denford S: Sex differences in perceptions of pain coping strategy usage. Eur J Pain 2009;13:629–634.
  13. Sage JI: Pain in Parkinson’s disease. Curr Treat Options Neurol 2004;6:191–200.
  14. Stacy MA, Murck H, Kroenke K: Responsiveness of motor and nonmotor symptoms of Parkinson disease to dopaminergic therapy. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:57–61.
  15. Ehrt U, Larsen JP, Aarsland D: Pain and its relationship to depression in Parkinson disease. Am J Geriatr Psychiatry 2009;17:269–275.
  16. McNamara P, Stavitsky K, Harris E, Szent-Imrey O, Durso R: Mood, side of motor symptom onset and pain complaints in Parkinson’s disease. Int J Geriatr Psychiatry 2010;25:519–524.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50